News, Links and Commentary
Thursday, October 20, 2005
Safety Trial Results for AMD Treatments
Several companies trialing treatments for age-related macular degeneration chose to announce positive data or results from safety trials at the Annual Meeting of the American Academy of Ophthalmology in Chicago last weekend.
Media releases outlining the results for trials of Alcon, Inc's drug Retaane, Sirna Therapeutics short interfering RNA (siRNA) molecule Sirna-027, Genaera's Evizon (with Visudyne photodynamic therapy), and VisionCare's Implantable Miniature Telescope are linked to below.
'Safety of Alcon's RETAANE Suspension Confirmed at 24 Months; Data Supports Clinical Equivalence to VISUDYNE' (Alcon, Inc, PharmaLive, 13 October 2005).
'VisionCare Pivotal Study Shows Improved Vision and Quality of Life Outcomes in Patients with Age-Related Macular Degeneration' (VisionCare Ophthalmic Technologies, Inc., PRNewswire, 19 October 2005).
'Genaera Presents Positive Preliminary Clinical Results for EVIZON(TM) for Treatment of Age-Related Macular Degeneration at the Annual AAO Meeting' (Genaera, Yahoo! Finance, 19 October 2005).
'Results Presented at the American Academy of Ophthalmology Demonstrate Clinical Benefit of a siRNA Compound in Humans' (Sirna Therapeutics, PRNewswire, 19 October 2005).
The San Francisco Chronicle also reported last month that Sirna Therapeutics are now working with drug company Allergan on their treatment for wet macular degeneration ('Sirna teams up with Allergan Firms to develop new treatments for eye disorders', 30 September 2005).
Media releases outlining the results for trials of Alcon, Inc's drug Retaane, Sirna Therapeutics short interfering RNA (siRNA) molecule Sirna-027, Genaera's Evizon (with Visudyne photodynamic therapy), and VisionCare's Implantable Miniature Telescope are linked to below.
'Safety of Alcon's RETAANE Suspension Confirmed at 24 Months; Data Supports Clinical Equivalence to VISUDYNE' (Alcon, Inc, PharmaLive, 13 October 2005).
'VisionCare Pivotal Study Shows Improved Vision and Quality of Life Outcomes in Patients with Age-Related Macular Degeneration' (VisionCare Ophthalmic Technologies, Inc., PRNewswire, 19 October 2005).
'Genaera Presents Positive Preliminary Clinical Results for EVIZON(TM) for Treatment of Age-Related Macular Degeneration at the Annual AAO Meeting' (Genaera, Yahoo! Finance, 19 October 2005).
'Results Presented at the American Academy of Ophthalmology Demonstrate Clinical Benefit of a siRNA Compound in Humans' (Sirna Therapeutics, PRNewswire, 19 October 2005).
The San Francisco Chronicle also reported last month that Sirna Therapeutics are now working with drug company Allergan on their treatment for wet macular degeneration ('Sirna teams up with Allergan Firms to develop new treatments for eye disorders', 30 September 2005).
Comments:
Post a Comment
